Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The final analysis of the PROFILE 1014 study, as concluded from NCT01154140, establishes a new benchmark for overall survival (OS) in patients with Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m). It underscores the benefit of crizotinib in extending survival for this group of patients. (1)
Crizotinib, as concluded from NCT00932893, demonstrates superiority over standard chemotherapy for patients who have previously been treated for advanced Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m) (2)
(1) …